Library
Peptide records
24 peptide records. Every entry follows the same structure.
Also on Strand: Sourcing — pathways, payment, and risk — and Papers and official documents, the citations behind each record.
Status
Evidence
24 records
Semaglutide
Metabolic
The best-documented incretin medicine in current use. Large randomized trials support clinically meaningful weight loss and glycemic improvement, with a well-characterized gastrointestinal adverse-effect profile and a boxed warning related to thyroid C-cell tumors in rodents.
Open recordTirzepatide
Metabolic
A dual incretin agonist with the strongest average weight-loss among currently approved peptide medicines. SURMOUNT and SURPASS programs are the evidence base. Same incretin-class cautions as GLP-1 monotherapy, plus the need to treat it as a prescription drug, not a wellness peptide.
Open recordRetatrutide
Metabolic
An investigational triple-incretin/glucagon agonist. Phase 2 weight-loss data were striking; it is not approved, dose and safety at scale are still being mapped, and it should not be treated as an available therapy.
Open recordInsulin
Metabolic
The original peptide medicine. More than a century of clinical use. It is a life-saving hormone replacement, not a performance or fat-loss tool — hypoglycemia from misuse is an emergency.
Open recordTesamorelin
Endocrine
The rare GH-axis peptide with a clear FDA indication. Visceral-fat reduction in HIV lipodystrophy is documented; that is not a license to use it as a general fat-loss or anti-aging drug.
Open recordTeriparatide
Endocrine
An anabolic osteoporosis medicine with fracture-reduction data. Lifetime duration is limited on the label because of rodent osteosarcoma findings. Not a general 'healing peptide.'
Open recordBremelanotide
Neuromodulatory
An FDA-approved on-demand injection for hypoactive sexual desire disorder in premenopausal women. The research-chemical name PT-141 is the same scaffold used off-label and in unregulated products — those are not the approved drug.
Open recordOxytocin
Endocrine
A workhorse obstetric medicine. Social-cognition and psychiatric uses remain experimental; intranasal research is mixed and dose/delivery are unsolved.
Open recordBPC-157
Regenerative
The internet's favorite 'healing peptide.' The rodent literature is large and often positive for gut, tendon, and muscle injury models. Quality human RCTs are essentially absent, and US compounding policy has moved against it.
Open recordTB-500
Regenerative
A research-market fragment of a naturally occurring actin-regulating peptide. Animal wound-healing data exist for Tβ4; the specific TB-500 product sold online is not a characterized human drug.
Open recordCJC-1295
Endocrine
A research GHRH analog with a small human PK/PD literature for the DAC form. It is not an approved GH-secretagogue medicine. Tesamorelin is the approved comparator in this class.
Open recordIpamorelin
Endocrine
A clean-looking GH secretagogue on paper, with sparse modern human data. Popular in 'peptide clinic' stacks. There is no approved indication and no large efficacy program.
Open recordGHK-Cu
Cosmetic
The peptide with the most plausible cosmetic evidence in this catalog. Still not a drug. Injectable 'GHK-Cu protocols' are a different, poorly documented practice from topical serum use.
Open recordSemax
Neuromodulatory
A Russian-developed nootropic peptide with domestic approvals for some neurologic indications. Western, independently replicated RCTs are scarce. Treat 'focus and neuroprotection' claims as regionally studied, not globally settled.
Open recordSelank
Neuromodulatory
The calmer sibling of Semax in the same development tradition. Anxiety and asthenia are the usual claims. Evidence is regional and small; it is not a validated alternative to standard anxiolytics.
Open recordEpithalon
Longevity
A longevity-circuit celebrity. Cell and animal telomere/pineal findings exist; they have not been converted into rigorous, replicated human outcome trials. 'Adds years' is marketing, not a result.
Open recordThymosin alpha-1
Immune
A real pharmaceutical in several countries (thymalfasin / Zadaxin) for hepatitis B and as an adjuvant in selected settings. Not FDA-approved for general 'immune optimization.' COVID-era use was exploratory.
Open recordMOTS-c
Mitochondrial
One of the more scientifically interesting mitochondrial-derived peptides. Mouse metabolic data are real. Jumping from that to a self-administered longevity drug is not.
Open recordElamipretide
Mitochondrial
The mitochondrial peptide that actually went through modern trial machinery. Results are mixed by indication: some rare-disease signals, several failed larger programs. That mixed record is more informative than hype.
Open recordCollagen peptides
Cosmetic
A food ingredient with a better evidence trail than most 'skin peptides' sold as injectables. Effects are modest. It is not equivalent to a prescription regenerative drug.
Open recordMelanotan II
Cosmetic
An unapproved tanning peptide with a concerning safety story: mole darkening, blood-pressure effects, nausea, and priapism. Afamelanotide (Scenesse) is the related approved medicine for a rare light-intolerance disease — it is not the same as gray-market MT-II.
Open recordKisspeptin-10
Endocrine
A legitimate endocrine research tool with human physiologic studies. Not a lifestyle peptide. Fertility-medicine development (including longer analogs) is the serious path; gray-market Kp-10 is not that path.
Open recordAOD-9604
Metabolic
A failed obesity drug candidate that reappeared on the peptide market. Fragmenting GH did not deliver GH-like fat loss in adequate trials. Treat current marketing as recycling, not a new discovery.
Open recordLL-37
Immune
An endogenous host-defense peptide, not a wellness supplement. Systemic or self-injected LL-37 has a plausible harm story (inflammation, cytotoxicity) that the market rarely prints.
Open record